1. Home
  2. USIO vs RNTX Comparison

USIO vs RNTX Comparison

Compare USIO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

HOLD

Current Price

$2.32

Market Cap

58.8M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USIO
RNTX
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
65.3M
IPO Year
1999
2017

Fundamental Metrics

Financial Performance
Metric
USIO
RNTX
Price
$2.32
$0.80
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.00
$10.00
AVG Volume (30 Days)
336.4K
477.3K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.16
EPS
0.01
N/A
Revenue
$28,200,535.00
N/A
Revenue This Year
$12.15
N/A
Revenue Next Year
$8.57
N/A
P/E Ratio
$227.00
N/A
Revenue Growth
12.69
N/A
52 Week Low
$1.03
$0.69
52 Week High
$3.06
$2.18

Technical Indicators

Market Signals
Indicator
USIO
RNTX
Relative Strength Index (RSI) 40.27 49.47
Support Level $2.11 $0.71
Resistance Level $2.61 $0.88
Average True Range (ATR) 0.17 0.06
MACD -0.07 -0.00
Stochastic Oscillator 10.71 34.69

Price Performance

Historical Comparison
USIO
RNTX

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: